Protalix BioTherapeutics (PLX) Change in Accured Expenses (2010 - 2026)

Protalix BioTherapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $820000.0 for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 163.86% year-over-year to $820000.0; the TTM figure through Mar 2026 stood at $2.4 million (up 190.07% YoY), while the FY2025 annual figure was $292000.0, down 58.05% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $820000.0, down from $4.3 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $4.3 million in Q4 2025, with the low at -$3.9 million in Q2 2022.
• The 5-year median for Change in Accured Expenses is $177000.0 (2023), against an average of $135235.3.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses jumped 503.01% in 2023, then tumbled 590.96% in 2024.
• Protalix BioTherapeutics' Change in Accured Expenses stood at -$366000.0 in 2022, then surged by 503.01% to $1.5 million in 2023, then declined by 7.39% to $1.4 million in 2024, then jumped by 216.62% to $4.3 million in 2025, then tumbled by 81.04% to $820000.0 in 2026.
• Business Quant data shows PLX's Change in Accured Expenses at $820000.0 in Q1 2026, $4.3 million in Q4 2025, and -$2.1 million in Q3 2025.